MYGN NASDAQ
Myriad Genetics, Inc.
1W: +8.0%
1M: -23.0%
3M: -8.9%
YTD: -36.3%
1Y: -12.1%
3Y: -79.0%
5Y: -85.7%
$3.82
-0.09 (-2.30%)
Weekly Expected Move ±11.2%
$3
$3
$4
$4
$4
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (50)
Down 29.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Myriad (MYGN)
Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
Myriad Genetics in record sell-off after Q1 miss
Myriad reiterates $860M-$880M 2026 revenue outlook while advancing Precise MRD and FirstGene launches
Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates
Myriad Genetics Non-GAAP EPS of -$0.09 misses by $0.02, revenue of $200.4M misses by $2.04M
Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business
Here are the major earnings after the close Tuesday
Earnings Scheduled For May 5, 2026
Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026
Analysts Estimate Myriad Genetics (MYGN) to Report a Decline in Earnings: What to Look Out for
Tempus AI Expands Strategic Partnership Amid Oncology Boom
Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026
Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting
Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting
Aberdeen Group plc Purchases 246,748 Shares of Myriad Genetics, Inc. $MYGN
JPMorgan Chase & Co. Sells 113,338 Shares of Myriad Genetics, Inc. $MYGN
What's Fueling TEM Diagnostics Segment's Strong 2026 Outlook?
What's Fueling TEM Diagnostics Segment's Strong 2026 Outlook?
Viridian Therapeutics (VRDN) Soars 5.6%: Is Further Upside Left in the Stock?
Assenagon Asset Management S.A. Has $7.18 Million Stock Holdings in Myriad Genetics, Inc. $MYGN
Myriad (MYGN) Up 4.1% Since Last Earnings Report: Can It Continue?
Why Myriad Genetics (MYGN) is a Top Growth Stock for the Long-Term
Why Myriad Genetics (MYGN) is a Top Momentum Stock for the Long-Term
Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer
Tempus AI Expands Clinical Validation of AI-Powered Cancer Diagnostics
Myriad Commercially Launches Precise MRD with Select Community Oncologists
Myriad Genetics jumps after Q4 beat; sees Q1 revenue rising 2%–4% Y/Y
MYGN Stock Up on Q4 Earnings and Revenue Beat, Gross Margin Down
Myriad Genetics outlines $860M–$880M revenue target for 2026 while advancing cancer care continuum strategy
Myriad Genetics, Inc. (MYGN) Q4 2025 Earnings Call Transcript
Here's What Key Metrics Tell Us About Myriad (MYGN) Q4 Earnings
Myriad Genetics (MYGN) Q4 Earnings and Revenues Surpass Estimates
Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution
Here are the major earnings after the close Monday
Myriad Genetics Q4 2025 Earnings Preview
Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026
Analysts Set Myriad Genetics, Inc. (NASDAQ:MYGN) PT at $9.44
AMH Equity Ltd Has $2.89 Million Stock Position in Myriad Genetics, Inc. $MYGN
Myriad Genetics, Inc. (MYGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Myriad Genetics, Inc. (NASDAQ:MYGN) Receives $10.50 Consensus Price Target from Analysts
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance
Myriad Genetics (NASDAQ:MYGN) Stock Passes Above 200 Day Moving Average – Here’s Why
Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference
Should Myriad Genetics Stock Stay in Your Portfolio Right Now?
Myriad Genetics (NASDAQ:MYGN) Share Price Passes Above 200-Day Moving Average – Here’s Why
Fisher Asset Management LLC Purchases 219,607 Shares of Myriad Genetics, Inc. $MYGN
Why Is Myriad (MYGN) Up 8.7% Since Last Earnings Report?
Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health